

(10) International Publication Number
WO 2014/041175 A1(43) International Publication Date
20 March 2014 (20.03.2014)

(51) International Patent Classification:

C07D 491/04 (2006.01) A61K 31/502 (2006.01)
C07D 495/04 (2006.01) A61P 25/00 (2006.01)
C07D 498/04 (2006.01)

(21) International Application Number:

PCT/EP2013/069173

(22) International Filing Date:

16 September 2013 (16.09.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/702,005 17 September 2012 (17.09.2012) US
61/702,371 18 September 2012 (18.09.2012) US

(71) Applicants: **ABBOTT GMBH & CO. KG** [DE/DE];
Max-Planck-Ring 2, 65205 Wiesbaden (DE). **ABBVIE INC.** [US/US]; 1 North Waukegan Road, North Chicago, Illinois 60064 (US).

(72) Inventors: **GENESTE, Hervé**; c/o AbbVie Deutschland GmbH & Co. KG, Knollstr. 50, 67061 Ludwigshafen (DE). **OCHSE, Michael**; c/o AbbVie Deutschland GmbH & Co. KG, Knollstr. 50, 67061 Ludwigshafen (DE). **DRESCHER, Karla**; c/o AbbVie Deutschland GmbH & Co. KG, Knollstr. 50, 67061 Ludwigshafen (DE). **JAKOB, Clarissa**; c/o AbbVie Inc., 1 North Waukegan Road, North Chicago, Illinois 60064 (US). **TORRENT, Maricel**; c/o AbbVie Inc., 12900 Heiden Circle, Unit 4407, Lake Bluff, Illinois 60044 (US). **YAO, Shanshan**; c/o AbbVie Inc., Round Lake Beach, Illinois 60073 (US). **ZHAO, Xiaoling**;

c/o AbbVie Inc., 1 North Waukegan Road, North Chicago, Illinois 60064 (US). **WANG, Liang**; c/o AbbVie Inc., Schaumburg, Illinois 60159 (US).

(74) Agent: **REITSTÖTTER, KINZEBACH & PARTNER**;
Ludwigsplatz 4, 67059 Ludwigshafen (DE).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A



(57) Abstract: The present invention relates to compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof, where in formula I the variables X, Y, Q¹, Q² have the following meanings: X is C-R³ or N; Q¹ is S or O and Q² is C-R⁴ or N and Q² is connected to X via a double bond while Q¹ is connected to X via a single bond; or Q² is S or O and Q¹ is C-R⁴ or N and Q¹ is connected to X via a double bond while Q² is connected to X via a single bond; Y is C-R⁵ or N; where in formula I the variables R¹, R², R³, R⁴ and R⁵ are as defined in the claims. The compounds of the formula I, the N-oxides, tautomers, the prodrugs and the pharmaceutically acceptable salts thereof are inhibitors of phosphodiesterase type 10A and to their use for the manufacture of a medicament and which thus are suitable for treating or controlling of medical disorders selected from neurological disorders and psychiatric disorders, for ameliorating the symptoms associated with such disorders and for reducing the risk of such disorders.